Abizer Gaslightwala - 12 Jun 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
CEO, Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
12 Jun 2025
Net transactions value
+$54,350
Form type
4
Filing time
16 Jun 2025, 17:00:17 UTC
Previous filing
12 Jun 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gaslightwala Abizer CEO, Director C/O AKARI THERAPEUTICS PLC, 22 BOSTON WHARF ROAD FL 7, BOSTON /s/ Torsten Hombeck, as Attorney-in-Fact 16 Jun 2025 0002049375

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $24,600 +20,000 +9.9% $1.23 221,428 12 Jun 2025 Direct F1, F2
transaction AKTX American Depositary Shares representing Ordinary Shares Award $29,750 +25,000 +11% $1.19 246,428 13 Jun 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS.
F3 On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS.